Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites

European Journal of Biochemistry

Volumn 269, Issue 16, 2002, Pages 4114-4120

  Fehér, Anita ^a   Weber, Irene T ^b   Bagossi, Péter ^a   Boross, Péter ^a   Mahalingam, Bhuvaneshwari ^b   Louis, John M ^c   Copeland, Terry D ^d   Torshin, Ivan Y ^b   Harrison, Robert W ^b   Tözsér, József ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b GEORGIA STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gag processing sites; HIV 1 proteinase; Molecular modeling; Oligopeptide substrates; Substrate specificity

Indexed keywords

GAG PROTEIN; OLIGOPEPTIDE; PROTEINASE; VIRUS ENZYME;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; CATALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME SUBSTRATE COMPLEX; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN PROCESSING; STRAIN DIFFERENCE; VIRUS NUCLEOCAPSID; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CARBAMATES; CATALYSIS; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, GAG; GENES, GAG; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; SULFONAMIDES; UREA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036039725     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2002.03105.x     Document Type: Article

References (50)

1. Retroviral proteinases
2. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance
3. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
4. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
5. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
6. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
7. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo
8. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
9. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
10. Drug resistance during indinavir therapy is caused by mutations in the pro-tease gene and its Gag substrate cleavage sites
11. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
12. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
13. Interaction of HIV-1 protease and gag gene mutations in response to amprenavir-selective pressure exerted in amprenavir-treated subjects - Contribution of Gag p6 changes L449F and P453L
14. In vitro evolution of the human immunodeficiency virus type 1 Gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure
15. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins
16. The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins
17. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
18. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors
19. Subsite preferences of retroviral proteinases
20. Variations in the p7/p1 gag cleavage region and virological response to HIV protease inhibitor
21. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
22. Impaired fitness of human immuno-deficiency virus type 1 variants with high-level resistance to pro-tease inhibitors
23. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
24. Autoprocessing of HIV-1 protease is tightly coupled to protein folding
25. Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes
26. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases
27. Program DYNAFIT for the analysis of enzyme kinetic data: Application to HIV proteinase
28. Molecular mechanics calculations on HIV-1 protease with peptide substrates correlate with experimental data
29. Molecular mechanics analysis of drug resistant mutants of HIV protease
30. Activating oligomerization as intermediate level of signal transduction: Analysis of protein-protein contacts and active sites in several glycolytic enzymes
31. 4 substrate binding site of HIV proteinases
32. 3′ subsites of HIV proteinases
33. Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity
34. Effect of substrate residues on the P2′ preference of retroviral proteinases
35. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine
36. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
37. Combining mutations in HIV-1 protease to understand mechanisms of resistance
38. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics
39. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance
40. Drug resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate
41. Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition
42. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH
43. Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration
44. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*Pro- cleavage sites
45. International perspectives on antiretroviral resistance. Resistance to protease inhibitors
46. The regulation of sequential processing of HIV-1 Gag by the viral protease
47. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development
48. Standardized and simplified nomenclature for proteins common to all retroviruses